News
Latest news: Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform
Access Press Release
Molecule to cure. Fast.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast.
Because humanity needs solutions, fast.
Watch our video
Welcome to Quotient Sciences
Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients.
Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, molecules need to become cures, fast. Because humanity needs solutions, fast.
Our services
At Quotient Sciences, we’ve streamlined the drug development process by providing pre-formulation screening, formulation development, first-in-human trials, and clinical & commercial manufacturing services all at one CDMO, allowing us to support drug programs from candidate selection through commercial supply.
Our latest updates
Discover what’s happening at Quotient Sciences
-
NewsQuotient Sciences SME comments on solubility & bioavailability challenges in Drug Development & Delivery feature articleJohn McDermott, Quotient Sciences' Executive Drug Development Consultant, discusses Integrated Development Strategies Overcome Solubility Challenges, in Drug Development & Delivery's Special Feature.
-
May 11SeminarBoston Lunch Seminar: Integrated Drug Substance & Drug Product Strategies- May 11Save your spot for our upcoming lunch seminar in Cambridge, MA on May 11 entitled: "Accelerating Development Through Integrated Drug Substance & Drug Product Strategies: Fully integrated programs to shorten the clinical pathway"
-
Info SheetHuman ADME CapabilitiesWith over 30 years’ experience as a world leading provider of human ADME 14C radiolabeled studies, we have the scientific expertise and operational know-how to design and deliver human ADME programs in preparation for NDA, MAA and global regulatory filings.
-
WebinarMoving Drug Substance Off the Critical Path — Streamlined Strategies to Accelerate to First-in-Human & BeyondJoin Quotient’s Director of Drug Development Consulting, Dr Stephen McQuaker Vice President of Bioanalysis, Dr Stuart McDougall, as he explores case studies to demonstrate how drug substance and drug product development plans can be accelerated through innovative science and expertise to get drug substance off the critical path.
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.